Male patients' preferences for opioid use treatment programs.


Journal

BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559

Informations de publication

Date de publication:
16 06 2023
Historique:
received: 03 11 2022
accepted: 08 06 2023
medline: 19 6 2023
pubmed: 17 6 2023
entrez: 16 6 2023
Statut: epublish

Résumé

A patient-centered approach to the treatment of substance use is helpful in achieving positive treatment outcomes. This study aimed to explore male patients' preferences for opioid use treatments. A qualitative study was conducted in Isfahan, a city in the center of Iran. The study sample included 64 male participants who had started treatment for opioid use disorder (OUD). Using a purposive maximum variation sampling procedure, seven treatment centers were selected as interview venues. The semi-structured face-to-face interviews were conducted in a private room in the selected centers. A hybrid inductive/deductive approach was used to thematize the interview transcripts. A total of three themes and 13 subthemes on opioid treatment preferences were identified: treatment concerns (anonymity, social stigma, fear of treatment distress, and family concerns), treatment attributes (treatment cost, location of the treatment center, treatment period, frequency of attendance, informed treatment, and treatment personnel), and treatment type (maintenance or abstinence and residential and community treatments). The study showed that all treatment programs were perceived to have their own strengths and weaknesses. The results showed that patients with OUD carefully compare the positive and negative aspects of existing treatment programs, and they consider a treatment program to be a package of favorable and non-favorable qualities. The identified themes could inform policymakers about the treatment preferences of male patients and provide an opportunity to promote better treatment options for OUD.

Sections du résumé

BACKGROUND
A patient-centered approach to the treatment of substance use is helpful in achieving positive treatment outcomes. This study aimed to explore male patients' preferences for opioid use treatments.
METHODS
A qualitative study was conducted in Isfahan, a city in the center of Iran. The study sample included 64 male participants who had started treatment for opioid use disorder (OUD). Using a purposive maximum variation sampling procedure, seven treatment centers were selected as interview venues. The semi-structured face-to-face interviews were conducted in a private room in the selected centers. A hybrid inductive/deductive approach was used to thematize the interview transcripts.
RESULTS
A total of three themes and 13 subthemes on opioid treatment preferences were identified: treatment concerns (anonymity, social stigma, fear of treatment distress, and family concerns), treatment attributes (treatment cost, location of the treatment center, treatment period, frequency of attendance, informed treatment, and treatment personnel), and treatment type (maintenance or abstinence and residential and community treatments). The study showed that all treatment programs were perceived to have their own strengths and weaknesses.
CONCLUSIONS
The results showed that patients with OUD carefully compare the positive and negative aspects of existing treatment programs, and they consider a treatment program to be a package of favorable and non-favorable qualities. The identified themes could inform policymakers about the treatment preferences of male patients and provide an opportunity to promote better treatment options for OUD.

Identifiants

pubmed: 37328768
doi: 10.1186/s12888-023-04939-x
pii: 10.1186/s12888-023-04939-x
pmc: PMC10273501
doi:

Substances chimiques

Analgesics, Opioid 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

440

Informations de copyright

© 2023. The Author(s).

Références

PLoS One. 2016 Jan 05;11(1):e0145817
pubmed: 26731679
AANA J. 2019 Jun;87(3):222-230
pubmed: 31584400
Hepat Mon. 2013 Aug 17;13(8):e12411
pubmed: 24069039
Subst Use Misuse. 2012 Jun;47(7):767-73
pubmed: 22416897
Int J Drug Policy. 2014 Nov;25(6):1041-6
pubmed: 25249444
Med Decis Making. 2015 Jan;35(1):114-31
pubmed: 25351843
Addict Sci Clin Pract. 2019 Dec 27;14(1):47
pubmed: 31882001
Addict Sci Clin Pract. 2017 Feb 24;12(1):6
pubmed: 28235415
J Med Toxicol. 2018 Dec;14(4):306-322
pubmed: 30377951
Addiction. 2016 Oct;111(10):1836-47
pubmed: 27177849
J Res Health Sci. 2014 Autumn;14(4):291-5
pubmed: 25503286
Int J Equity Health. 2018 Jun 11;17(1):75
pubmed: 29890990
Subst Abus. 2023 Jan-Apr;44(1):41-50
pubmed: 37226910
Iran J Public Health. 2013 Aug;42(8):896-902
pubmed: 26056645
Prog Community Health Partnersh. 2014 Spring;8(1):99-107
pubmed: 24859107
Asian J Psychiatr. 2020 Dec;54:102313
pubmed: 32738562
Am Fam Physician. 2019 Oct 1;100(7):416-425
pubmed: 31573166
J Subst Abuse Treat. 2022 Jul;138:108752
pubmed: 35277306
Addiction. 2008 Sep;103(9):1484-92
pubmed: 18636999
J Subst Abuse Treat. 2022 Jun;137:108690
pubmed: 34930575
N Engl J Med. 2012 Mar 1;366(9):780-1
pubmed: 22375967
Addict Health. 2013 Winter-Spring;5(1-2):16-20
pubmed: 24494153
Subst Abus. 2022;43(1):767-773
pubmed: 35112998
Health Expect. 2006 Mar;9(1):25-36
pubmed: 16436159
J Adv Nurs. 2016 Dec;72(12):2954-2965
pubmed: 27221824
Drug Alcohol Depend. 2018 Jan 01;182:48-57
pubmed: 29136566
Drug Alcohol Depend. 2021 Apr 1;221:108649
pubmed: 33640679
J Subst Abuse Treat. 2023 Jan;144:108918
pubmed: 36403456
BMJ Open. 2018 Oct 17;8(10):e022267
pubmed: 30337310
JAMA. 2009 Oct 28;302(16):1805-6
pubmed: 19861674
JAMA Psychiatry. 2019 Feb 1;76(2):208-216
pubmed: 30516809
J Subst Abuse Treat. 2018 Aug;91:57-68
pubmed: 29910015
J Subst Abuse Treat. 2002 Apr;22(3):157-9
pubmed: 12039619
J Subst Abuse Treat. 2018 Jan;84:78-87
pubmed: 29195596
J Subst Abuse Treat. 2020 Dec;119:108146
pubmed: 33138929
Aust J Prim Health. 2023 Mar 20;:
pubmed: 36934460
Drug Alcohol Depend. 2021 Apr 1;221:108651
pubmed: 33667783
Asian J Psychiatr. 2015 Aug;16:78-83
pubmed: 26168763
Ann Intern Med. 2017 Feb 21;166(4):268-278
pubmed: 27919103
Drug Alcohol Depend. 2019 Apr 1;197:168-182
pubmed: 30831429

Auteurs

Mostafa Amini-Rarani (M)

Health Management and Economics Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

Maryam Moeeni (M)

Social Determinants of Health Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. mmoeini1387@gmail.com.

Koen Ponnet (K)

Faculty of social sciences, imec-mict-ghent university, Ghent, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH